Kristina M. Brooks

JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies

Gina A. Montealegre Sanchez, Adam Reinhardt, Suzanne Ramsey et al. · Journal of Clinical Investigation · 2018 · 521 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +17

Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Hanna Kim, Kristina M. Brooks, Cheng Cai Tang et al. · Clinical Pharmacology & Therapeutics · 2017 · 131 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal Disease

Ofer Zimmerman, Berenice Rösler, Christa S. Zerbe et al. · Open Forum Infectious Diseases · 2017 · 66 citations · Full text

Life Sciences, Dermatology, Infectious Diseases +17

Cytokine-Mediated Systemic Adverse Drug Reactions in a Drug–Drug Interaction Study of Dolutegravir With Once-Weekly Isoniazid and Rifapentine

Kristina M. Brooks, Jomy George, Alice K. Pau et al. · Clinical Infectious Diseases · 2018 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran

Parag Kumar, Lori A. Gordon, Kristina M. Brooks et al. · Antimicrobial Agents and Chemotherapy · 2017 · 57 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16